Standout Papers

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and... 2010 2026 2015 2020 1.7k
  1. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial (2010)
    M. William Audeh, James Carmichael et al. The Lancet
  2. Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer (2012)
    Jonathan A. Ledermann, Philipp Harter et al. New England Journal of Medicine
  3. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial (2014)
    Jonathan A. Ledermann, Philipp Harter et al. The Lancet Oncology
  4. Ovarian cancer (2016)
    Ursula A. Matulonis, Anil K. Sood et al. Nature Reviews Disease Primers
  5. Place of Death: Correlations With Quality of Life of Patients With Cancer and Predictors of Bereaved Caregivers' Mental Health (2010)
    Alexi A. Wright, Nancy L. Keating et al. Journal of Clinical Oncology
  6. Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer (2007)
    Stephen A. Cannistra, Ursula A. Matulonis et al. Journal of Clinical Oncology
  7. Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1 (2015)
    Brooke E. Howitt, Sachet A. Shukla et al. JAMA Oncology
  8. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer (2016)
    Kyle C. Strickland, Brooke E. Howitt et al. Oncotarget
  9. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study (2014)
    Joyce F. Liu, William T. Barry et al. The Lancet Oncology
  10. PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer (2018)
    Liya Ding, Hye‐Jung Kim et al. Cell Reports
  11. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial (2019)
    Kathleen N. Moore, Angeles Alvarez Secord et al. The Lancet Oncology
  12. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial (2016)
    Jonathan A. Ledermann, Philipp Harter et al. The Lancet Oncology
  13. Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer (2019)
    Daniela Matei, Virginia L. Filiaci et al. New England Journal of Medicine
  14. Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study (2023)
    Ursula A. Matulonis, Domenica Lorusso et al. Journal of Clinical Oncology
  15. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer (2022)
    Qiwei Wang, Johann S. Bergholz et al. Nature Communications
  16. Clinical and translational advances in ovarian cancer therapy (2023)
    Panagiotis A. Konstantinopoulos, Ursula A. Matulonis Nature Cancer
  17. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer (2023)
    Lucy Gilbert, Ana Oaknin et al. Gynecologic Oncology

Immediate Impact

6 by Nobel laureates 10 from Science/Nature 88 standout
Sub-graph 1 of 20

Citing Papers

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
Designing antibodies as therapeutics
2022 Standout
11 intermediate papers

Works of Ursula A. Matulonis being referenced

Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients (pts) with solid tumors likely to express NaPi2b.
2019
Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): Initial results of an expansion cohort from FORWARD II, a phase Ib study
2018
and 9 more

Author Peers

Author Last Decade Papers Cites
Ursula A. Matulonis 8004 13055 7706 424 22.4k
Amit M. Oza 6780 10496 7237 581 21.0k
Michael Friedländer 9605 15324 7333 486 26.8k
Jonathan A. Ledermann 7733 8893 4841 277 16.8k
Andrew Berchuck 6748 5699 8006 353 19.5k
Beth Y. Karlan 6389 6294 7818 328 18.4k
Robert L. Coleman 9133 7443 7503 657 22.5k
Karen H. Lu 8090 6678 7308 425 21.0k
Gini F. Fleming 5227 7997 4050 326 16.2k
Martin Gore 4853 14140 12791 377 29.0k
Douglas A. Levine 7181 6587 9041 253 21.8k

All Works

Loading papers...

Rankless by CCL
2026